The State Council of the People’s Republic of China has adopted a new regulatory framework governing the clinical research and translational application of emerging biomedical technologies. The measure marks a further consolidation of China’s life sciences regulatory system and establishes a more structured regime for the oversight of innovative biomedical research and its progression into clinical use.
The framework is expected to significantly affect life sciences companies, research institutions, sponsors, and international investors, particularly in relation to clinical trial governance, compliance requirements, and development pathways for new therapies. It strengthens regulatory oversight of clinical research, introduces mandatory scientific and ethical review procedures, and establishes centralized filing and approval mechanisms, alongside a structured risk management and enforcement system. The reform reflects China’s continued effort to enhance regulatory rigor while supporting the responsible development and translation of biomedical innovation.